TriangleVactosertib (NCT06044311)
Vactosertib trial for Adenocarcinoma Esophagus (NCT06044311). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, poorly differentiated or grade-three esophageal or gastroesophageal-junction adenocarcinoma, stage two or three, who could undergo surgery.
The idea: test vactosertib, which blocks TGF-beta receptor signaling involved in tumor growth. Tablets are taken twice daily, five days weekly, for two weeks before standard preoperative treatment and two weeks afterward. Standard treatment may be chemotherapy or chemoradiation. PET scans and endoscopic biopsies assess changes before surgery is considered.
This phase 2 study plans 25 patients. Melissa Lumish leads one recruiting US site at University Hospitals in Cleveland.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.